

2-11-04 Image

Request For

Continued Examination (RCE) **Transmittal**

Address to: Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Application Number	09/724,288	
Filing Date	November 28, 2000	
First Named Inventor	Schenk, Dale B.	
Art Unit	1647	
Examiner Name	Sharon L. Turner	
Attorney Docket Number	15270J-004765US	

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).					
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.					
i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on					
ii.					
b. 🛛 Encl	losed				
i. 🛮 🗸	mendment/Reply		Information Disclosure Sta		
<u>ii. □ </u>	Affidavit(s)/ Declaration(s)	iv. 🗵	Other 13 Replacement Di	rawings Sheets	
2. Miscellan	eous				
a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period ofmonths. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)					
b. Other					
3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.					
a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 20-1430					
i. RCE fee required under 37 CFR 1.17(e) ii. Extension of time fee (37 CFR 1.136 and 1.17)					
iii.					
l = - · · · · · · · · · · · · · · · · · ·					
c. Payment by credit card (Form PTO-2038 enclosed) WARNING: Information on this form may become public. Credit card information should not					
be included on this form. Provide credit card information and authorization of PTO-2038.					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED					
Name (Print /Type)	Rosemarie L. Celli	Registrat	ion No. (Attorney/Agent)	42,397	
Signature	Kosemane L. all.	Date	February 9, 2004		
CERTIFICATE OF MAILING OR TRANSMISSION					
I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Express Mail No. EV 337 295 346 US service under 37 CFR 1.10, addressed to: Mail Stop: RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 23313-1450, on the date indicated below.					
Name (Print /Type)	Ronald Anton				
Signature	Ronald anton	Date	February 9, 2004		

60137449 v1

ate of Deposit: Februan

I hereby certify that this is being deposited with the United States Postal Service "express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Mail Stop: RCE Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TOWNSEND and TOWNSEND and CREW LLP

Ronald Anton

Application No.: 09/724,288

Applicant:

Schenk et al.

Filed:

November 28, 2000

TC/AU:

1647

Examiner:

Sharon L. Turner

For: PREVENTION AND TREATMENT

OF AMYLOIDOGENIC DISEASE

Atty Docket No.: 15270J-004765US

Customer No.: 20350

Confirmation No.: 9431

Mail Stop RCE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT

Sir:

This paper is submitted with a Request for Continued Examination (RCE) in response to the Final Office Action mailed September 9, 2003 for the above-referenced application. Please enter the following amendments and remarks:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begin on page 3 of this paper.

Amendments to the Drawings begin on page 8 of this paper and include an attached replacement sheet and an annotated sheet showing changes.

Remarks/Arguments begin on page 10 of this paper.